Malaria – Pipeline Review, H2 2016

Global Markets Direct’s, ‘Malaria – Pipeline Review, H2 2016’, provides an overview of the Malaria pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Malaria, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Malaria and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Malaria

The report reviews pipeline therapeutics for Malaria by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Malaria therapeutics and enlists all their major and minor projects

The report assesses Malaria therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Malaria

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Malaria

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Malaria pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

4SC AG

Acetylon Pharmaceuticals, Inc.

Actelion Ltd

Agilvax Inc

Akshaya Bio Inc.

Allergy Therapeutics Plc

Amura Holdings Limited

Anacor Pharmaceuticals, Inc.

Artificial Cell Technologies, Inc.

AstraZeneca Plc

Bharat Biotech International Limited

Callaghan Innovation Research Ltd.

Carna Biosciences, Inc.

CEL-SCI Corporation

Celgene Corporation

Cellceutix Corporation

Chong Kun Dang Pharmaceutical Corp.

Cilian AG

Daiichi Sankyo Company, Limited

DesignMedix, Inc.

Eisai Co., Ltd.

GenVec, Inc.

Genzyme Corporation

GlaxoSmithKline Plc

Hager Biosciences, LLC

Horizon Pharma Plc

iBio, Inc.

Imaxio SA

Immtech Pharmaceuticals, Inc.

Immunovaccine Inc

IPCA Laboratories Limited

IRBM Science Park SpA

Jenrin Discovery, Inc.

Jomaa Pharma GmbH

Kancera AB

Kymab Limited

Lipocure Ltd.

Lipotek Pty Ltd.

LondonPharma Ltd

Merck & Co., Inc.

Merck KGaA

MerLion Pharmaceuticals Pte Ltd

Microbiotix, Inc.

Mitsubishi Tanabe Pharma Corporation

Mucosis B.V.

Mymetics Corporation

Novartis AG

PaxVax, Inc.

Pfenex Inc.

Pfizer Inc.

Protein Potential, LLC

Rodos BioTarget GmbH

Sanaria Inc.

Sanofi

SBI Pharmaceuticals Co., Ltd.

Selecta Biosciences, Inc.

Sigma-Tau S.p.A.

Takeda Pharmaceutical Company Limited

Telormedix SA

Tomegavax, Inc.

VLP Biotech, Inc.

VLP Therapeutics, LLC

Zydus Cadila Healthcare Limited

Table of Contents

Table of Contents

Table of Contents 2

Introduction 6

Malaria Overview 7

Therapeutics Development 8

Malaria - Therapeutics under Development by Companies 10

Malaria - Therapeutics under Investigation by Universities/Institutes 15

Malaria - Pipeline Products Glance 19

Malaria - Products under Development by Companies 22

Malaria - Products under Investigation by Universities/Institutes 29

Malaria - Companies Involved in Therapeutics Development 36

Malaria - Therapeutics Assessment 99

Drug Profiles 111

Malaria - Dormant Projects 362

Malaria - Discontinued Products 375

Malaria - Product Development Milestones 377

Appendix 390

List of Tables

List of Tables

Number of Products under Development for Malaria, H2 2016 30

Number of Products under Development for Malaria – Comparative Analysis, H2 2016 31

Number of Products under Development by Companies, H2 2016 32

Number of Products under Development by Companies, H2 2016 (Contd..1) 33

Number of Products under Development by Companies, H2 2016 (Contd..2) 34

Number of Products under Development by Companies, H2 2016 (Contd..3) 35

Number of Products under Development by Companies, H2 2016 (Contd..4) 36

Number of Products under Investigation by Universities/Institutes, H2 2016 37

Number of Products under Investigation by Universities/Institutes, H2 2016 (Contd..1) 38

Number of Products under Investigation by Universities/Institutes, H2 2016 (Contd..2) 39

Number of Products under Investigation by Universities/Institutes, H2 2016 (Contd..3) 40

Comparative Analysis by Late Stage Development, H2 2016 41

Comparative Analysis by Clinical Stage Development, H2 2016 42

Comparative Analysis by Early Stage Development, H2 2016 43

Products under Development by Companies, H2 2016 44

Products under Development by Companies, H2 2016 (Contd..1) 45

Products under Development by Companies, H2 2016 (Contd..2) 46

Products under Development by Companies, H2 2016 (Contd..3) 47

Products under Development by Companies, H2 2016 (Contd..4) 48

Products under Development by Companies, H2 2016 (Contd..5) 49

Products under Development by Companies, H2 2016 (Contd..6) 50

Products under Investigation by Universities/Institutes, H2 2016 51

Products under Investigation by Universities/Institutes, H2 2016 (Contd..1) 52

Products under Investigation by Universities/Institutes, H2 2016 (Contd..2) 53

Products under Investigation by Universities/Institutes, H2 2016 (Contd..3) 54

Products under Investigation by Universities/Institutes, H2 2016 (Contd..4) 55

Products under Investigation by Universities/Institutes, H2 2016 (Contd..5) 56

Products under Investigation by Universities/Institutes, H2 2016 (Contd..6) 57

Malaria – Pipeline by 4SC AG, H2 2016 58

Malaria – Pipeline by Acetylon Pharmaceuticals, Inc., H2 2016 59

Malaria – Pipeline by Actelion Ltd, H2 2016 60

Malaria – Pipeline by Agilvax Inc, H2 2016 61

Malaria – Pipeline by Akshaya Bio Inc., H2 2016 62

Malaria – Pipeline by Allergy Therapeutics Plc, H2 2016 63

Malaria – Pipeline by Amura Holdings Limited, H2 2016 64

Malaria – Pipeline by Anacor Pharmaceuticals, Inc., H2 2016 65

Malaria – Pipeline by Artificial Cell Technologies, Inc., H2 2016 66

Malaria – Pipeline by AstraZeneca Plc, H2 2016 67

Malaria – Pipeline by Bharat Biotech International Limited, H2 2016 68

Malaria – Pipeline by Callaghan Innovation Research Ltd., H2 2016 69

Malaria – Pipeline by Carna Biosciences, Inc., H2 2016 70

Malaria – Pipeline by CEL-SCI Corporation, H2 2016 71

Malaria – Pipeline by Celgene Corporation, H2 2016 72

Malaria – Pipeline by Cellceutix Corporation, H2 2016 73

Malaria – Pipeline by Chong Kun Dang Pharmaceutical Corp., H2 2016 74

Malaria – Pipeline by Cilian AG, H2 2016 75

Malaria – Pipeline by Daiichi Sankyo Company, Limited, H2 2016 76

Malaria – Pipeline by DesignMedix, Inc., H2 2016 77

Malaria – Pipeline by Eisai Co., Ltd., H2 2016 78

Malaria – Pipeline by GenVec, Inc., H2 2016 79

Malaria – Pipeline by Genzyme Corporation, H2 2016 80

Malaria – Pipeline by GlaxoSmithKline Plc, H2 2016 81

Malaria – Pipeline by Hager Biosciences, LLC, H2 2016 82

Malaria – Pipeline by Horizon Pharma Plc, H2 2016 83

Malaria – Pipeline by iBio, Inc., H2 2016 84

Malaria – Pipeline by Imaxio SA, H2 2016 85

Malaria – Pipeline by Immtech Pharmaceuticals, Inc., H2 2016 86

Malaria – Pipeline by Immunovaccine Inc, H2 2016 87

Malaria – Pipeline by IPCA Laboratories Limited, H2 2016 88

Malaria – Pipeline by IRBM Science Park SpA, H2 2016 89

Malaria – Pipeline by Jenrin Discovery, Inc., H2 2016 90

Malaria – Pipeline by Jomaa Pharma GmbH, H2 2016 91

Malaria – Pipeline by Kancera AB, H2 2016 92

Malaria – Pipeline by Kymab Limited, H2 2016 93

Malaria – Pipeline by Lipocure Ltd., H2 2016 94

Malaria – Pipeline by Lipotek Pty Ltd., H2 2016 95

Malaria – Pipeline by LondonPharma Ltd, H2 2016 96

Malaria – Pipeline by Merck & Co., Inc., H2 2016 97

Malaria – Pipeline by Merck KGaA, H2 2016 98

Malaria – Pipeline by MerLion Pharmaceuticals Pte Ltd, H2 2016 99

Malaria – Pipeline by Microbiotix, Inc., H2 2016 100

Malaria – Pipeline by Mitsubishi Tanabe Pharma Corporation, H2 2016 101

Malaria – Pipeline by Mucosis B.V., H2 2016 102

Malaria – Pipeline by Mymetics Corporation, H2 2016 103

Malaria – Pipeline by Novartis AG, H2 2016 104

Malaria – Pipeline by PaxVax, Inc., H2 2016 105

Malaria – Pipeline by Pfenex Inc., H2 2016 106

Malaria – Pipeline by Pfizer Inc., H2 2016 107

Malaria – Pipeline by Protein Potential, LLC, H2 2016 108

Malaria – Pipeline by Rodos BioTarget GmbH, H2 2016 109

Malaria – Pipeline by Sanaria Inc., H2 2016 110

Malaria – Pipeline by Sanofi, H2 2016 111

Malaria – Pipeline by SBI Pharmaceuticals Co., Ltd., H2 2016 112

Malaria – Pipeline by Selecta Biosciences, Inc., H2 2016 113

Malaria – Pipeline by Sigma-Tau S.p.A., H2 2016 114

Malaria – Pipeline by Takeda Pharmaceutical Company Limited, H2 2016 115

Malaria – Pipeline by Telormedix SA, H2 2016 116

Malaria – Pipeline by Tomegavax, Inc., H2 2016 117

Malaria – Pipeline by VLP Biotech, Inc., H2 2016 118

Malaria – Pipeline by VLP Therapeutics, LLC, H2 2016 119

Malaria – Pipeline by Zydus Cadila Healthcare Limited, H2 2016 120

Assessment by Monotherapy Products, H2 2016 121

Assessment by Combination Products, H2 2016 122

Number of Products by Stage and Target, H2 2016 124

Number of Products by Stage and Mechanism of Action, H2 2016 127

Number of Products by Stage and Route of Administration, H2 2016 130

Number of Products by Stage and Molecule Type, H2 2016 132

Malaria – Dormant Projects, H2 2016 384

Malaria – Dormant Projects (Contd..1), H2 2016 385

Malaria – Dormant Projects (Contd..2), H2 2016 386

Malaria – Dormant Projects (Contd..3), H2 2016 387

Malaria – Dormant Projects (Contd..4), H2 2016 388

Malaria – Dormant Projects (Contd..5), H2 2016 389

Malaria – Dormant Projects (Contd..6), H2 2016 390

Malaria – Dormant Projects (Contd..7), H2 2016 391

Malaria – Dormant Projects (Contd..8), H2 2016 392

Malaria – Dormant Projects (Contd..9), H2 2016 393

Malaria – Dormant Projects (Contd..10), H2 2016 394

Malaria – Dormant Projects (Contd..11), H2 2016 395

Malaria – Dormant Projects (Contd..12), H2 2016 396

Malaria – Discontinued Products, H2 2016 397

Malaria – Discontinued Products (Contd..1), H2 2016 398

List of Figures

List of Figures

Number of Products under Development for Malaria, H2 2016 30

Number of Products under Development for Malaria – Comparative Analysis, H2 2016 31

Number of Products under Development by Companies, H2 2016 32

Number of Products under Investigation by Universities/Institutes, H2 2016 37

Comparative Analysis by Late Stage Development, H2 2016 41

Comparative Analysis by Clinical Stage Development, H2 2016 42

Comparative Analysis by Early Stage Products, H2 2016 43

Assessment by Monotherapy Products, H2 2016 121

Assessment by Combination Products, H2 2016 122

Number of Products by Top 10 Targets, H2 2016 123

Number of Products by Stage and Top 10 Targets, H2 2016 123

Number of Products by Top 10 Mechanism of Actions, H2 2016 126

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 126

Number of Products by Routes of Administration, H2 2016 129

Number of Products by Stage and Routes of Administration, H2 2016 129

Number of Products by Top 10 Molecule Types, H2 2016 131

Number of Products by Stage and Top 10 Molecule Types, H2 2016 131

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports